Vicarious Surgical Inc. a next-generation robotics technology company, announced that it received a notice from the New York Stock Exchange (NYSE) on April 10, 2025, regarding non-compliance with continued listing standards.
According to the notice, the Company no longer meets the NYSE’s requirements under Section 802.01B of the Listed Company Manual. Specifically, Vicarious Surgical’s average market capitalization over a consecutive 30 trading-day period fell below $50 million, and its last reported stockholders’ equity, as of December 31, 2024, was also under $50 million. As of April 9, 2025, the Company’s 30-day average market cap was approximately $47.4 million.
This notice does not affect the Company’s day-to-day operations.
Per NYSE procedures, Vicarious Surgical has 45 days from the date of the notice to submit a plan outlining actions it has taken or intends to take to restore compliance within 18 months. If the Company fails to submit an acceptable plan on time, the NYSE may initiate delisting proceedings.
During the 18-month cure period, Vicarious Surgical’s Class A common stock will remain listed and traded on the NYSE, subject to the Company’s continued compliance with other NYSE requirements and quarterly progress reviews. The stock will trade under the symbol “RBOT” with the “.BC” designation to indicate its “below criteria” status, which will be removed upon regaining compliance.
The notice has no impact on the Company’s SEC reporting obligations.
Vicarious Surgical is currently evaluating all available options to regain compliance with the NYSE listing standards.
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next-generation robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts.
